Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025Frontiers in PharmacologyOpen Access

The role of the lysine histone methylase KMT2D in chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLina SchlemmingerINInga NagelIVInga Vater

Discussion

Loading...

Member takes

Overview

Analysis reveals KMT2D mutation promotes TKI resistance in chronic myeloid leukemia, indicating epigenetic factors are critical.

Key Points

  • Loss of KMT2D contributes to increased resistance to imatinib in chronic myeloid leukemia, highlighting a significant therapeutic hurdle.
  • Upregulation of CCNE2 in KMT2D variant cells correlates with enhanced proliferation under imatinib treatment, suggesting a bypass mechanism.
  • Experimental knockdown of KMT2D showed impaired drug responsiveness, confirming its role as a tumor suppressor in CML.
  • Restoring KMT2D expression reversed imatinib resistance, indicating that targeting KMT2D could be a potential therapeutic strategy.

Cite This Study

Schlemminger et al. (2025) studied this question.

synapsesocial.com/papers/68d42c58713b0b5dfea6facbhttps://doi.org/10.3389/fphar.2025.1652373
View Full Paper
Ask AI
Bookmark
Share